Clinical trial
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With…
NCT00486642 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00486642 |
|---|---|
| Title | Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy |
| Official title | A Phase 2 Study of GW786034 (Pazopanib) With or Without Bicalutamide in Hormone Refractory Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hormone-Resistant Prostate Cancer, Recurrent Prostate Carcinoma |
| Intervention type | Drug, Other |
| Interventions | Bicalutamide, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study |
| Enrollment | 23 |
| Start date | Sep 1, 2007 |
| Primary completion | Aug 1, 2015 |
| Completion | Sep 1, 2015 |
| First posted | Jun 14, 2007 |
| Last update posted | May 24, 2017 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: